Icahn Says Future Is Big Pharma Will Buy Biotech (BIIB, AMLN)

Currently, my friend Mike Huckman is interviewing Carl Icahn over the phone on CNBC and asked him about what he plans to do with Biogen Idec (Nasdaq: BIIB) and Amylin (Nasdaq: AMLN). Icahn says he is not looking to sell Biogen Idec and Amylin Pharmaceuticals anytime soon. First, management needs to streamline things and get both of their operations in order.

You May Also Be Interested In

• Biogen (BIIB) call put ratio 3.7 calls to 1 put with a focus on September calls
• Wolfe Research Upgrades Biogen (BIIB) to Outperform